This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections

This study has been completed.
Sponsor:
Collaborator:
Taisho Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Mylan Inc.
ClinicalTrials.gov Identifier:
NCT01097005
First received: February 26, 2010
Last updated: July 28, 2016
Last verified: March 2015
Results First Received: June 17, 2015  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: Mycobacterium Infections, Atypical

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients will be registered using a central registration system. The investigators will register eligible patients with the registration center via FAX by 7 days after initiation of clarithromycin treatment.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Clarithromycin Those with an exposure

Participant Flow:   Overall Study
    Clarithromycin
STARTED   466 [1] 
Analysis of Safety   441 [2] 
Analysis of NTM Lung Disease   340 [3] 
Analysis of Bacilli Negative Conversion   285 [4] 
Analysis of CGI   249 [5] 
COMPLETED   101 
NOT COMPLETED   365 
Case Report Form not collected                18 
Subjects cannot visit the hospital                1 
Poor medication compliance                1 
No examination data available                244 
Deviation from exclusion criteria                37 
Adverse Event                14 
Discontinuance by complication                50 
[1] number of participants who were enrolled for this study.
[2] number of participants who could be measured for Adverse Events
[3] number of participants who contributed to the Baseline data
[4] number of participants who were analysed for bacilli negative conversion
[5] number of participants who were measured for Clinical Global Improvement (CGI)



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Clarithromycin Those with an exposure

Baseline Measures
   Clarithromycin 
Overall Participants Analyzed 
[Units: Participants]
 340 
Age, Customized 
[Units: Participants]
 
<45 years   15 
45-64 years   136 
65-74 years   126 
>=75 years   62 
unknown   1 
Gender, Customized 
[Units: Participants]
 
Female   256 
Male   83 
unknown   1 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Bacilli Negative Conversion Rate   [ Time Frame: During the treatment with clarithromycin, from 40 days to 1232 days ]

2.  Secondary:   Efficacy Evaluation Using the 4-rank Scale of "Effective", "Ineffective", "Deterioration", or "Impossible" by the Investigator   [ Time Frame: When treatment with clarithromycin is discontinued, from 40 days to 1232 days ]

3.  Secondary:   Bacteriological Relapse Related to Duration of Clarithromycin Administration   [ Time Frame: 36 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Takao Miki, Medical Affairs
Organization: Mylan EPD Japan
e-mail: takao.miki@mylan.com



Responsible Party: Mylan Inc.
ClinicalTrials.gov Identifier: NCT01097005     History of Changes
Other Study ID Numbers: P10-765
Study First Received: February 26, 2010
Results First Received: June 17, 2015
Last Updated: July 28, 2016